Altered Differentiation and Inflammation Profiles Contribute to Enhanced Innate Responses in Severe COPD Epithelium to Rhinovirus Infection.
ALI culture
COPD
bronchial epithelial cells
differentiation
host innate response
human rhinovirus
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2022
2022
Historique:
received:
07
09
2021
accepted:
24
01
2022
entrez:
14
3
2022
pubmed:
15
3
2022
medline:
15
3
2022
Statut:
epublish
Résumé
Respiratory viral infections are closely associated with COPD exacerbations, hospitalisations, and significant morbidity and mortality. The consequences of the persisting inflammation and differentiation status in virus associated severe disease is not fully understood. The aim of this study was to evaluate barrier function, cellular architecture, the inflammatory response in severe COPD bronchial epithelium to human rhinovirus (HRV) induced pathological changes and innate immune responses. Well-differentiated primary bronchial epithelial cells (WD-PBECs) derived from severe COPD patients and age-matched healthy controls were cultured in the air-liquid interface (ALI) model. The differentiation phenotype, epithelial barrier integrity, pathological response and cytokine secreting profile of these cultures before and after HRV infection were investigated. WD-PBECs derived from severe COPD patients showed aberrant epithelium differentiation with a decreased proportion of ciliated cells but increased numbers of club cells and goblet cells compared with healthy controls. Tight junction integrity was compromised in both cultures following HRV infection, with heightened disruptions in COPD cultures. HRV induced increased epithelial cell sloughing, apoptosis and mucus hypersecretion in COPD cultures compared with healthy controls. A Th1/Th2 imbalance and a strong interferon and pro-inflammatory cytokine response was also observed in COPD cultures, characterized by increased levels of IFNγ, IFNβ, IP-10, IL-10 and decreased TSLP and IL-13 cytokine levels prior to HRV infection. Significantly enhanced basolateral secretion of eotaxin 3, IL-6, IL-8, GM-CSF were also observed in both mock and HRV infected COPD cultures compared with corresponding healthy controls. In response to HRV infection, all cultures displayed elevated levels of IFNλ1 (IL-29), IP-10 and TNFα compared with mock infected cultures. Interestingly, HRV infection dramatically reduced IFNλ levels in COPD cultures compared with healthy subjects. An altered differentiation phenotype and cytokine response as seen in severe COPD WD-PBECs may contribute to increased disease susceptibility and an enhanced inflammatory response to HRV infection.
Sections du résumé
Background
UNASSIGNED
Respiratory viral infections are closely associated with COPD exacerbations, hospitalisations, and significant morbidity and mortality. The consequences of the persisting inflammation and differentiation status in virus associated severe disease is not fully understood. The aim of this study was to evaluate barrier function, cellular architecture, the inflammatory response in severe COPD bronchial epithelium to human rhinovirus (HRV) induced pathological changes and innate immune responses.
Methods
UNASSIGNED
Well-differentiated primary bronchial epithelial cells (WD-PBECs) derived from severe COPD patients and age-matched healthy controls were cultured in the air-liquid interface (ALI) model. The differentiation phenotype, epithelial barrier integrity, pathological response and cytokine secreting profile of these cultures before and after HRV infection were investigated.
Results
UNASSIGNED
WD-PBECs derived from severe COPD patients showed aberrant epithelium differentiation with a decreased proportion of ciliated cells but increased numbers of club cells and goblet cells compared with healthy controls. Tight junction integrity was compromised in both cultures following HRV infection, with heightened disruptions in COPD cultures. HRV induced increased epithelial cell sloughing, apoptosis and mucus hypersecretion in COPD cultures compared with healthy controls. A Th1/Th2 imbalance and a strong interferon and pro-inflammatory cytokine response was also observed in COPD cultures, characterized by increased levels of IFNγ, IFNβ, IP-10, IL-10 and decreased TSLP and IL-13 cytokine levels prior to HRV infection. Significantly enhanced basolateral secretion of eotaxin 3, IL-6, IL-8, GM-CSF were also observed in both mock and HRV infected COPD cultures compared with corresponding healthy controls. In response to HRV infection, all cultures displayed elevated levels of IFNλ1 (IL-29), IP-10 and TNFα compared with mock infected cultures. Interestingly, HRV infection dramatically reduced IFNλ levels in COPD cultures compared with healthy subjects.
Conclusion
UNASSIGNED
An altered differentiation phenotype and cytokine response as seen in severe COPD WD-PBECs may contribute to increased disease susceptibility and an enhanced inflammatory response to HRV infection.
Identifiants
pubmed: 35280870
doi: 10.3389/fmed.2022.741989
pmc: PMC8916560
doi:
Types de publication
Journal Article
Langues
eng
Pagination
741989Informations de copyright
Copyright © 2022 Guo-Parke, Linden, Mousnier, Scott, Killick, Borthwick, Fisher, Weldon, Taggart and Kidney.
Déclaration de conflit d'intérêts
IS and HK are employed by AstraZeneca. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Am J Respir Crit Care Med. 2014 Mar 1;189(5):532-9
pubmed: 24471509
Thorax. 2019 Jan;74(1):18-32
pubmed: 29991510
COPD. 2020 Feb;17(1):59-64
pubmed: 31910693
Science. 2020 Aug 7;369(6504):712-717
pubmed: 32527928
Curr Allergy Asthma Rep. 2016 Apr;16(4):30
pubmed: 26960297
Respir Res. 2017 Oct 24;18(1):180
pubmed: 29065892
Respir Med. 2008 Nov;102(11):1575-80
pubmed: 18672353
J Clin Invest. 1995 Jul;96(1):549-57
pubmed: 7615827
Am J Respir Crit Care Med. 2002 May 15;165(10):1404-9
pubmed: 12016104
Respir Res. 2016 Sep 07;17(1):111
pubmed: 27604339
Eur Respir J. 2014 Jul;44(1):87-96
pubmed: 24627537
Thorax. 2009 Aug;64(8):671-6
pubmed: 19213775
J Allergy Clin Immunol. 1999 Mar;103(3 Pt 1):458-62
pubmed: 10069880
Lancet. 2007 Sep 1;370(9589):765-73
pubmed: 17765526
Front Nutr. 2021 Sep 07;8:674258
pubmed: 34557509
Lancet Respir Med. 2016 Jul;4(7):574-584
pubmed: 27283230
Virol J. 2011 Jan 27;8:43
pubmed: 21272337
Expert Opin Drug Discov. 2014 Jun;9(6):609-28
pubmed: 24850530
Am J Physiol Lung Cell Mol Physiol. 2020 Nov 1;319(5):L884-L886
pubmed: 33050739
Sci Rep. 2019 Nov 29;9(1):17963
pubmed: 31784664
Respirology. 2015 Jul;20(5):722-9
pubmed: 25868842
Am J Physiol Lung Cell Mol Physiol. 2019 Dec 1;317(6):L893-L903
pubmed: 31513433
J Interferon Cytokine Res. 2014 Mar;34(3):162-8
pubmed: 24102578
Am J Respir Crit Care Med. 2013 Oct 1;188(7):842-51
pubmed: 23952745
JCI Insight. 2017 Apr 6;2(7):e90443
pubmed: 28405612
Thorax. 2004 Oct;59(10):850-4
pubmed: 15454650
Chest. 2006 Feb;129(2):317-324
pubmed: 16478847
Am J Physiol Lung Cell Mol Physiol. 2015 Apr 1;308(7):L619-27
pubmed: 25595648
Pediatr Res. 2010 Jan;67(1):17-22
pubmed: 19755931
Tanaffos. 2018 Jan;17(1):13-21
pubmed: 30116274
Sci Rep. 2015 Feb 02;5:8163
pubmed: 25641363
Clin Sci (Lond). 2017 Jul 1;131(13):1541-1558
pubmed: 28659395
Nat Med. 2006 Sep;12(9):1023-6
pubmed: 16906156
J Allergy Clin Immunol. 2016 Jul;138(1):16-27
pubmed: 27373322
Am J Physiol Lung Cell Mol Physiol. 2020 Oct 1;319(4):L603-L619
pubmed: 32783615
Toxicol In Vitro. 2010 Apr;24(3):981-7
pubmed: 20060463
Ann Am Thorac Soc. 2016 Mar;13 Suppl 1:S55-63
pubmed: 27027954
Am J Respir Crit Care Med. 2010 Aug 1;182(3):332-40
pubmed: 20395558
J Biol Chem. 1999 Apr 2;274(14):9707-20
pubmed: 10092659
PLoS One. 2019 Jun 6;14(6):e0217803
pubmed: 31170225
Clin Chest Med. 2020 Sep;41(3):421-438
pubmed: 32800196
Methods Mol Biol. 2016;1442:119-39
pubmed: 27464691
Eur Respir Rev. 2019 Mar 14;28(151):
pubmed: 30872396
Am J Respir Crit Care Med. 2005 Mar 15;171(6):645-51
pubmed: 15591468
Respir Res. 2019 Jul 12;20(1):150
pubmed: 31299975
BMC Genom Data. 2021 Oct 12;22(1):41
pubmed: 34635059
J Exp Med. 2005 Mar 21;201(6):937-47
pubmed: 15781584
Int J Chron Obstruct Pulmon Dis. 2017 Feb 08;12:541-550
pubmed: 28223794
Am J Respir Crit Care Med. 2016 Dec 15;194(12):1494-1505
pubmed: 27373892
PeerJ. 2015 Aug 27;3:e1199
pubmed: 26336642